论文部分内容阅读
本文作者对60例急性非淋巴细胞白血病(ANLL)试用左旋咪唑,以确定后者能否增加化疗效果。60例ANLL分两组,第1组30例单用化疗,称无左旋咪唑组;第2组30例在化疗同时应用左旋咪唑称左旋咪唑组。左旋咪唑每次45mg/m~2,每天2次,每周连续3天。结果60例ANLL患者中,可评价者56例。无左旋咪唑组62%(18/29例)达到完全缓解;用左旋咪唑组59%(16/27例)完全缓解,两组诱导缓解时间相似(P=0.205)。尽管生存曲线显示左旋咪唑组始终优于对照组,但两组首次完全缓解期相似(无左旋咪唑
The authors tested levamisole in 60 patients with acute non-lymphocytic leukemia (ANLL) to determine whether the latter could increase chemotherapy effects. Sixty patients with ANLL were divided into two groups. 30 patients in the first group were treated with chemotherapy alone and no levamisole group; 30 patients in the second group were treated with levamisole and levamisole. Levamisole, 45 mg/m 2 at a time, 2 times a day for 3 consecutive days. Results Of the 60 patients with ANLL, 56 were evaluable. In the levamisole-free group, 62% (18/29) achieved complete remission; in the levamisole group, 59% (16/27) had complete remission, and induction of remission was similar between the two groups (P=0.205). Although the survival curve showed that the levamisole group was always superior to the control group, the first complete remission period was similar between the two groups (no levamisole